BioStem TECHNOLOGIES

Company Presentation

MARCH 2026

Forward Looking Statements

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies, Inc. (the “Company”, “us” or “we”) with respect to anticipated future performance. Words such as “expects,” anticipates,” “intends,” “plans,” “likely,” “will,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward looking statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore such statements included in this presentation may not prove to be accurate. Forward-looking statements in this presentation relate to our: ongoing commitment to deliver advance wound care solutions to improve the quality of life for patients; expectations regarding growth and the related driving factors; expectations regarding commercialization and opportunities in hospital-based sites of services; expectations regarding the performance of direct sales representatives and independent sales agents; expectations regarding the assignment or transfer of key GPO contracts; expectations regarding the innovation of new placental platform technologies and complementary modalities; expectations regarding intellectual property values and uses; estimates and expectations regarding the total addressable wound market; strategic growth initiatives, including but not limited to strategic acquisitions, expansion into new markets and expansion of our commercial team; expectations regarding further penetration of current markets; the opportunity for leverage on sales and marketing expenses; ability to capitalize and report clinically significant data over our competitors; and expectations regarding future operations, financial positions, estimated revenue, forecasts, prospects and plans; expectations regarding the timing of completion of the 2024 and 2025 audits; and expectations regarding our plans to uplist to the Nasdaq Capital Market.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. The following is a list of risks, among others, that could cause actual results to differ materially from those contemplated by the forward-looking statements: the risk that the Company may not be able to achieve or maintain profitability in the future; the risk that the Company has derived the majority of our revenue from a distribution agreement; the risk that a material amount of revenues and accounts receivable are concentrated in one or more customers, and that if the Company loses or experiences a significant reduction in sales, the Company’s revenues may decrease substantially and materially affect the Company’s results of operations and financial condition; the audit of the Company’s restated financial statements and the impact of any changes to the accounting treatment of the Company’s revenue and expenses; significant and continuing competition, which could adversely affect the Company's business, results or operations and financial condition; the Company’s ability to achieve its strategic and financial objectives depends in part on the successful integration of newly acquired assets and the continued effectiveness of its commercial organization; the Company has incurred significant losses since inception and may incur losses in the future; and the impact of any changes to the reimbursement levels for the Company's products; challenges associated with integrating new products, technologies, or operational capabilities—including unanticipated costs, delays, or resource demands—could adversely affect expected synergies, operational performance, and long-term value creation. In addition, the Company’s performance remains dependent on the sustained productivity and effectiveness of its salesforce. Any inability to recruit, retain, train, or motivate sales personnel, or disruptions that negatively impact sales execution, could impair revenue growth and hinder the successful commercialization of current and future assets; the risk that the Company will be unable to maintain its use of intellectual property; the Company’s ability to convince physicians that the products are safe and effective alternatives to existing treatments and that the Company’s products should be used in their procedures; the risk that the Company may be unable to successfully market its products to the end users of such products; the risk that the Company will be unable to maintain adequate levels of reimbursement from public and private insurers and health systems which may result in changes to the ways in which the Company’s products are reimbursed in various sites of service and, as a result may adversely impact the Company’s financial results; the risk that the Company will be unable to produce sufficient data to support coverage of our products under the finalized LCDs or otherwise satisfy any regulatory requirements needed to ensure our products are eligible for Medicare reimbursement; the risk that the FDA may in the future determine that certain products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the Public Health Service Act, and may require that the Company revise its labeling and marketing claims for these products or require the Company to suspend sales of such products until FDA pre-market clearance or approval is obtained, either of which could adversely affect the Company’s business, results of operations, and financial condition; the risk that the rate of reimbursement and coverage for the purchase of the Company’s products by government and private insurance may change; the impact of any changes in applicable laws or regulations; and the risk that the Company may not meet the listing standards of the Nasdaq Stock Market.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. There may be additional risks about which the Company is presently unaware of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Our Mission

To **create** and **deliver** the most **advanced wound healing technologies** in the **world**

*In **Relentless Pursuit** of Healing*

Investment Highlights

Driving adoption of perinatal tissue allografts

Differentiated Technology	Strong Foundation	Growth Engine
3 Industry-Leading Technologies BioREtain®, CryoTek® and SteriTek®	**Large Treated Patient Population** Thousands of patients treated annually	**Expansion of Addressable Market** End market opportunity across multiple specialty areas
6 Perinatal-Derived Allograft Brands Including our newly acquired Neox™ and Clarix™ families	**Library of Clinical Data** 90+ clinical publications across all products	**Broadening Commercial Reach** Adding Sales Reps to pursue green field opportunities in major US markets
Industry-Leading IP Portfolio 58 issued U.S. patents and 68 pending	**National Sales Force** ~18 direct BioTissue reps and >30 independent agents plus GPO contracts	**Pipeline: 510(k) Clearance Pending** 510(k) submitted in September 2025 for Flo-based product

BioStem TECHNOLOGIES

The Need for Perinatal Allografts

*Regenerative Medicine promotes faster healing and reduces complications**

Economic Impact[1]

Infections and complications cost the health system an estimated $30B+ each year

Patient Impact[2]

- ~155,000 lower limb amputations annually
- ~800,000 DFU hospitalizations annually

Faster Healing

Perinatal allografts maintain an optimal healing environment, accelerating tissue regeneration

Infection Prevention

Sterile, timely care prevents infections, which can lead to costly complications like sepsis

Minimize Scarring & Adhesion

Consistent care promotes smooth tissue healing, reducing visible scarring

Pain Management & Comfort

Controlling inflammation reduces patient discomfort, supports mobility, and improves adherence to care

Reduced Complications

Effective management reduces the risk of chronic non-healing wounds and, in severe cases, amputation

BioStem TECHNOLOGIES

*These statements are general in nature and pertain to the overall characteristics of the regenerative medicine field. They are not claims regarding our products, nor are they intended to suggest that our products are approved by the Food and Drug Administration (FDA) or have any specific medical benefits.

[1] "The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention"; R Douglas Scott II, CDC March 2009

[2] Patient Impact data from Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers, American Diabetes Association, December 2022. https://doi.org/10.2337/dci22-0043

Large and Underserved ~$23B US Soft Tissue Allograft Opportunity

Driving adoption of perinatal tissue allografts for multiple market segments

1 Orthopedics/Sports Medicine

US TAM: ~$2.3B

Knee Osteoarthritis | Soft Tissue Repair| Trauma

2 Chronic Wound Care

US TAM: ~$15B

DLU | VLU | Pressure Ulcers | Pilonidal Cyst | Hidradenitis Suppurativa

3 Foot & Ankle

US TAM: ~$1.1B

Tendon Repair | Joint Replacement & Reconstruction | Trauma



4 Urology/ Colorectal

US TAM: ~$1.5B

Radical Prostatectomy | Urethral / Ureteral Strictures | Reconstruction

5 Spine

US TAM: ~$1.6B

Facet Joint Pain | Hardware Adhesion Barrier

6 Women's Health

US TAM: ~$1.8B

Pelvic Floor Recon | Myomectomy| Hysterectomy | Ovarian Cystectomy

BioStem TECHNOLOGIES

*These numbers are based off company data on file

Our Regenerative Medicine Solutions

A complete portfolio of perinatal tissue allografts

NON-WOUND / SURGICAL — Orthopedics/Sports Medicine · Foot & Ankle · Urology / Colorectal · Spine · Women's Health

WOUND — Chronic Wound Care

Clarix 1K

Cryopreserved amnion and UTA allograft

SOURCE	THICKNESS
Amnion & UTA	1,000 µm
MAX SIZE	**STORAGE**
8.0 × 3.0 cm	❄ Freezer

Clarix 100

Cryopreserved amnion allograft

SOURCE	THICKNESS
Amnion Only	100 µm
MAX SIZE	**STORAGE**
7.0 × 7.0 cm	❄ Freezer

Clarix Flo

Particulate amnion and UTA allograft

SOURCE	THICKNESS
Amnion & UTA	N/A
MAX SIZE	**STORAGE**
N/A	🌡 Room Temp

Neox 1K

Cryopreserved amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	1,000 µm
MAX SIZE	**STORAGE**
8.0 × 3.0 cm	❄ Freezer

Neox 100

Cryopreserved amnion wound allograft

SOURCE	THICKNESS
Amnion Only	100 µm
MAX SIZE	**STORAGE**
7.0 × 7.0 cm	❄ Freezer

Neox RT

Cryopreserved amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	~600 µm
MAX SIZE	**STORAGE**
8.0 × 3.0 cm	🌡 Room Temp

Neox Flo

Particulate amnion and UTA wound allograft

SOURCE	THICKNESS
Amnion & UTA	N/A
MAX SIZE	**STORAGE**
N/A	🌡 Room Temp

VENDAJE

Dehydrated human amniotic membrane allograft

SOURCE	THICKNESS
Amnion + Int.	100 µm
MAX SIZE	**STORAGE**
10.0 × 20.0 cm	🌡 Room Temp

VENDAJE AC

Dehydrated amniotic membrane — amnion, int. chorion

SOURCE	THICKNESS
Amnion, Int., Chorion	N/A
MAX SIZE	**STORAGE**
10.0 × 20.0 cm	🌡 Room Temp

Products added from acquisition of BioTissue surgical assets

UTA – ultra-thick amniotic membrane

Product Roadmap

Utilize regulatory approvals to strengthen claims, enhance product marketability and expand payor coverage



BioStem Regenerative Technology Platforms

Best in class platforms that preserve the natural properties of perinatal tissue to create leading allografts

BioRetain®

The patented six-step BioREtain® process is gentle, minimally invasive, and preserves the natural integrity of the amniotic tissue/ components critical to the inherent wound healing process

CryoTek® Technology

CryoTek cryopreservation is a tissue processing method that preserves the innate biological and structural integrity of the natural placental tissue

SteriTek® Preservation

SteriTek preservation process yields a shelf-stable product while maintaining the natural hydration of the tissue

BioStem TECHNOLOGIES

Note: CryoTek and SteriTek information from BioTissue website

BioREtain® Optimizes Retention of Natural Tissue Properties

Demonstrated superiority over market leader

IL-1ra



Anti-inflammatory Cytokines
Modulate inflammation by suppressing pro-inflammatory molecules

PDGF-BB



Growth Factors
Promote tissue regeneration and reduce scarring

Hyaluronan



Hyaluronan
Promotes stem cell proliferation

Collagen 1a1



Extracellular Matrix
Provides a scaffold for new tissue generation

- Standardized reporting of amnion and amnion/chorion allograft data for wound care. Sabol, TJ, Tran, GS, Matuszewski, J, Weston, W. Health Science Reports, Aug. 2022.
- Competitors 1, 2 and 4 are all dehydrated amniochorion products.

BioStem TECHNOLOGIES

Results of DFU and Ambulate Studies

Multiple robust randomized control trials supporting the technology

Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers[1]

- Trial design to meet the most **rigorous patient selection** and clinical endpoint standards
- BR-AC achieved **superior clinical outcomes** in this patient population
- The **probability of healing** in the BR-AC arm was **53%** while the probability of healing in the standard of care arm was **31%**

Ambulate Study[2]

- Trial design to treat the most **severe chronic wounds** – Wagner Grade III/IV
- **66% closure** at 26 weeks
- Average **1.67±0.87 applications** to achieve closure
- **High healing rate** for complex DFUs that are often excluded from clinical trials

1. Company Data on file
2. Caporusso, et al. Wound Repair Regen. December 2025

Expanding to Multi-Channel Commercial Infrastructure

Distributors

- Leverage current relationship with Venture
- Add partners to target the physician office

Direct

- Establish relationship with physician champion
- Gain access to new sites of service
- Grow the team

GPO

- Premier, Vizient, HPG
- Process to add Vendaje AC
- Bundled under DRG

Independent Sales Agents & Distributors

- Leverage current relationships
- Expand geographic reach





BioStem TECHNOLOGIES

*Indicates Mobile wound care , Long term Care, Skill Nursing, and Physician Office

Expanding Payor Mix Towards Commercial Reimbursement

Compelling unit economics in the hospital setting

Physician Office Market

Vendaje



CMS Payor

Commercial Payor

Hospital Market

Neox, Clarix



BioStem TECHNOLOGIES

Multiple Commercial Growth Levers



EXPAND CHANNEL & GEOGRAPHIC FOOTPRINT

DRIVE ADOPTION WITH PEER-to-PEER SELLING

INCREASE PAYOR COVERAGE /PATIENT ACCESS

Primary revenue generating states

How $127/cm² Presents an Opportunity

Return to evidence-based selling

	2025	2026
Physician Office & Associated Care Setting	ASP + 6% plus ~$150 application fee	$127/cm² fixed + ~$150 application fee
Hospital Outpatient & Wound Care Centers	~$1,800 bundled rate per visit	$127/cm² fixed + ~$750 application fee
Ambulatory Surgery Centers (ASC)	~$860 bundled rate per visit	$127/cm² fixed + ~$400 application fee

- **Favorable gross margin even at $127/cm² in all sites of service**
- **$127/cm² is a step up in the Hospital and ASC settings by removing the bundled payment**

World-Class Manufacturing

AATB® accredited, cGTP facility



- State of the art, vertically integrated manufacturing facility
- Currently processing 30k sq cm monthly
- Capacity up to 100K sq cm monthly to support future growth
- 6,100 sq ft dedicated area; 3,000 sq ft ISO clean room space
- Located in Pompano Beach, FL
- Executed a manufacturing supply agreement with BioTissue for Neox and Clarix products for 12+ months
- Current facility has the capability and capacity to manufacture Neox and Clarix products post the supply agreement





BioStem TECHNOLOGIES

Management Team

Accomplished team with deep industry experience



Jason Matuszewski LSSBB
Chief Executive Officer



Andrew Van Vurst CTBS
Chief Operating Officer



Brandon Poe
Chief Financial Officer



Michael Fortunato CPA
Chief Accounting Officer



Barry Hassett
Chief Commercial Officer



Wendy Weston PhD, CTBS
Vice President, R&D



Noah Agron
Vice President, Corporate Finance & Strategy



Lita Lilly
Vice President of Sales



Grace Tran
Director of Lab Operations



Taylor Sabol
Director of Quality



Michael Milberg
Government Affairs



Nick McCoy
Clinical Operations

MIDI HEALTH · CAIRE Niterra Group · SCJohnson A family company at work for a better world · genome MEDICAL · illumina · BioTissue · VIVEX BIOLOGICS

BioStem TECHNOLOGIES

Financial Outlook

Strong Financial Profile

- Investing for growth in our surgical revenue base; BioTissue assets generated $29M in 2025 and largely unaffected by CMS price changes
- Transition period for wound business in 1H 2026 as market digests CMS payment changes
- Efficient manufacturing process (and the future technology transfer of BioTissue products) will continue to deliver healthy gross margins*
- Track record of delivering positive Adjusted EBITDA and cashflow
- $16M cash balance post BioTissue asset acquisition

Uplist to Nasdaq

- Company plans to uplist to the Nasdaq Capital Market
- Appointed KPMG as the independent registered public accountant
- 2024 and 2025 audits expected to be completed in 1Q 26
- Audit completion enables pursuit of uplisting

* BioTissue will provide manufacturing services for Neox and Clarix products for 12+ months via our Supply Agreement

Well-Positioned to Capitalize on Opportunities in Perinatal Allografts

Generating Evidence

- Complete the remaining VLU and DFU RCTs in 2026 to strengthen clinical foundation
- Expand technical data and evidence demonstrating superiority versus competitors to drive market growth
- Generate retrospective real-world data
- Case series to support expansion of surgical applications

Diversifying Portfolio

- BioTissue acquisition diversifies the product portfolio and catalyzes revenue growth
- Innovate new technologies on the placental platform
- Explore additional strategic acquisitions:
  - Synergistic patents
  - Alternative biologic technologies
  - Advanced wound care – external devices
  - Technology assets to drive revenue growth

Driving Growth

- Large, growing market with significant adjacent opportunities
- Leverage and expand direct and indirect commercial sales team
- Add distribution partners in office/mobile markets
- Leverage GPO contracts to expand our footprint in the hospital/surgical market
- Increase patient access to existing products

BioStem TECHNOLOGIES

Thank you

MARCH 2026

BSEM